Global Hemophilia Treatment Market
Global hemophilia treatment market was valued at $10.2bn in 2015 and is forecast to grow at a modest 5.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $17.2bn.
Hemophilia is a rare inherited bleeding disorder whereby blood does not clot normally. Predominantly, hemophilia is classified as hemophilia A and hemophilia B. Hemophilia A occurs when the body is unable to produce adequate amounts of factor VIII (FVIII), while patients with hemophilia B are unable to produce adequate amounts of factor IX (FIX).
The hemophilia market has grown at a steady pace over the last 5 years and is expected to grow for next several years driven by greater prophylaxis treatment in the adult and pediatric populations, and new extended half-life factor replacement therapies entering the market.
Bayer is expected to file its extended half-life FVIII product BAY94-9027 in late 2016 and Novo Nordisk is expected to file its extended half-life product N8-GP in 2018. Once approved, these products can gradually gain more share of this market over the next decade.